rs559406 — PTPN2

Intronic PTPN2 variant whose G allele reduces T-cell protein tyrosine phosphatase (TC-PTP) activity, amplifying JAK-STAT signaling and conferring susceptibility to psoriasis and related autoimmune conditions

See your personal result for PTPN2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PTPN2 rs559406 — When the Immune Brake Slips

Every immune response needs a brake. T-cell protein tyrosine phosphatase — known as TC-PTP, encoded by PTPN2 — is one of the body's primary molecular brakes on the JAK-STAT signaling cascade11 JAK-STAT signaling cascade
Janus kinase–signal transducer and activator of transcription: a core cytokine signaling pathway that controls immune cell proliferation, differentiation, and inflammation. The rs559406 variant is an intronic SNP in the PTPN2 gene on chromosome 18. Its G allele — the reference allele in the human genome — is associated with subtly reduced TC-PTP function, amplified cytokine signaling, and increased susceptibility to psoriasis and related inflammatory conditions. The T allele confers lower risk.

The Mechanism

TC-PTP removes activating phosphate groups from JAK1, JAK2, JAK3, STAT1, STAT3, and STAT5 — the very proteins that translate cytokine receptor signals into inflammatory gene transcription. When TC-PTP activity is reduced, these kinases and transcription factors remain phosphorylated longer, sustaining inflammatory responses well past the point where they should resolve. In T cells specifically, this translates to enhanced Th1 differentiation, expanded cytotoxic CD8+ responses, and impaired regulatory T-cell (Treg) maintenance — three converging forces toward autoimmunity.

The intronic location of rs559406 suggests it influences PTPN2 expression or mRNA splicing rather than protein structure directly, a pattern consistent with other PTPN2 variants in strong linkage disequilibrium at this locus (including rs189321722 rs1893217
An intronic PTPN2 variant in perfect LD with rs2542151, the primary IBD susceptibility SNP at this locus; same gene region, different LD block from rs559406). The specific functional consequence of the rs559406 G allele at the molecular level has not yet been characterized in published studies; the risk designation rests on genome-wide association data.

The Evidence

A genome-wide association study from the VA Million Veteran Program — one of the largest genetic studies ever conducted (>635,000 participants) — identified rs559406-G as a genome-wide significant risk allele for psoriasis33 identified rs559406-G as a genome-wide significant risk allele for psoriasis
GCST90476186/90476190; G allele beta ≈0.073, p ≈1×10⁻¹¹; ~16,700 psoriasis cases vs ~430,000 controls, European ancestry. The modest beta coefficient (≈0.073 on a log-odds scale) corresponds to an odds ratio of approximately 1.08 per G allele — a small but population-relevant effect.

Functional studies at the gene level help explain why PTPN2 variants influence autoimmune disease. In a mouse model of type 1 diabetes, T-cell-specific PTPN2 deficiency markedly accelerated diabetes onset and increased incidence, while also triggering colitis and Sjögren syndrome44 T-cell-specific PTPN2 deficiency markedly accelerated diabetes onset and increased incidence, while also triggering colitis and Sjögren syndrome
Mice lacking PTPN2 only in T cells showed substantially higher T1D incidence; CD8+ T-cell PTPN2 loss alone was sufficient to drive beta-cell destruction. In human pancreatic beta cells, silencing PTPN2 increased IFN-α/TNF-α-driven cell death by 20-50%55 silencing PTPN2 increased IFN-α/TNF-α-driven cell death by 20-50%
Mechanism: increased JNK1 and BIM phosphorylation drives apoptosis; blocking JNK1 or BIM restored survival, identifying beta-cell protection as a direct function of TC-PTP activity. In intestinal epithelial cells, the CD-associated PTPN2 variant rs1893217 impaired autophagosome formation and skewed inflammatory responses toward Th1-type IFN-γ secretion66 rs1893217 impaired autophagosome formation and skewed inflammatory responses toward Th1-type IFN-γ secretion
Impaired muramyl-dipeptide-induced autophagy in both intestinal epithelial cells and monocytes carrying the risk genotype, demonstrating how a slight reduction in phosphatase activity can tip the immune balance toward chronic inflammation.

At the clinical level, PTPN2 variants at this locus predict response to targeted therapies. The closely related intronic variant rs1893217 (in the same gene region, in linkage disequilibrium with rs2542151) showed that in the Swiss IBD Cohort (1,073 CD and 734 UC patients), C-allele carriers had greater disease severity but — paradoxically — better response to anti-TNF antibodies (adalimumab, infliximab, certolizumab)77 Swiss IBD Cohort (1,073 CD and 734 UC patients), C-allele carriers had greater disease severity but — paradoxically — better response to anti-TNF antibodies (adalimumab, infliximab, certolizumab)
Significant association between PTPN2 C-allele carrier status and anti-TNF treatment success in both CD and UC. A separate study found that the PTPN2 rs7234029 risk allele was associated with substantially higher nonresponse rates to anti-IL-12/23 biologics in Crohn's disease88 substantially higher nonresponse rates to anti-IL-12/23 biologics in Crohn's disease
89.9% nonresponse in risk allele carriers vs 67.6% in non-carriers (p=0.005), illustrating how PTPN2 genotype can guide biologic selection.

Practical Actions

Carrying the rs559406 G allele — particularly two copies — reflects a JAK-STAT signaling system that runs slightly hotter than average. The clinical consequence depends heavily on cumulative immune burden: other genetic risk factors, infection history, microbiome composition, and environmental stressors all interact with this baseline. For people who already have psoriasis or another autoimmune condition associated with JAK-STAT overactivation, the PTPN2 variant has actionable pharmacogenomic implications — JAK inhibitors (tofacitinib, upadacitinib, baricitinib) target the exact pathway that TC-PTP normally dampens, and preliminary evidence suggests PTPN2 risk carriers may have heightened responsiveness to these therapies.

For people with inflammatory bowel disease, PTPN2 genotype at this locus appears to predict biologic response patterns that can guide prescribing — though the evidence is currently at the literature/gene-association level, not formal CPIC/DPWG guideline status.

Interactions

PTPN2 functions synergistically with PTPN22 (rs2476601, R620W), which encodes a related phosphatase active in lymphocyte receptor signaling. Both genes act as negative regulators of T-cell activation — PTPN2 through JAK-STAT, PTPN22 through TCR signaling — and carrying risk variants in both simultaneously creates a broader impairment of immune braking. Reviews of PTPN2/PTPN22 combined risk have noted additive effects on T1D and IBD susceptibility, suggesting that evaluating both variants together provides a more complete picture of autoimmune risk than either alone.

Intronic PTPN2 variants at this locus may also interact with JAK-pathway modifying variants in cytokine receptor genes (IL2RA, IL7R, IL21R). The IBD literature has documented epistasis between PTPN2 rs2542151 and autophagy gene ATG16L1 rs2241879 (p=0.024), suggesting convergent effects on mucosal homeostasis when both pathways are impaired.

Drug Interactions

tofacitinib dose_adjustment literature
upadacitinib dose_adjustment literature
adalimumab dose_adjustment literature
infliximab dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

TT Protected Phosphatase Normal

Two copies of the protective T allele; TC-PTP function and JAK-STAT regulation at baseline

You carry two copies of the T allele at rs559406, the lower-risk genotype at this locus. Your TC-PTP phosphatase activity at the PTPN2 gene is not reduced by this variant, meaning the JAK-STAT inflammatory signaling cascade operates within its normal regulatory range at this locus. Your genetic risk for psoriasis conferred by rs559406 is at or below population average.

Globally, approximately 23% of people carry two T alleles. In European populations, TT is more common (about 30%) because the T allele frequency is higher there (~55%) than in East Asian populations (~15%). This genotype does not provide immunity to autoimmune disease — many other genetic and environmental factors contribute — but this particular PTPN2 variant is not adding to your risk.

GT Moderate Phosphatase Risk Intermediate

One G allele; mildly elevated JAK-STAT tone with modest increase in psoriasis susceptibility

The G allele at rs559406 tags an intronic haplotype in PTPN2 associated with slightly reduced TC-PTP regulatory activity. TC-PTP normally removes activating phosphate groups from JAK1, JAK2, JAK3, STAT1, STAT3, and STAT5 after cytokine stimulation. With one G allele, the inflammatory signaling brake is mildly impaired — enough to shift susceptibility to immune-mediated conditions, but not at the severity of two G copies. The practical impact is context-dependent: the variant is most consequential for individuals who already have other autoimmune risk factors or an active inflammatory disease where JAK-STAT dysregulation is central to pathogenesis.

GG Heightened Phosphatase Risk High Risk

Two copies of the G allele; the highest rs559406 risk genotype with amplified JAK-STAT activity

Homozygous GG individuals carry two copies of the rs559406 risk haplotype in PTPN2. The additive effect means both alleles contribute reduced TC-PTP activity, resulting in more sustained phosphorylation of JAK1, JAK2, JAK3, STAT1, STAT3, and STAT5 following cytokine stimulation. In preclinical models, complete loss of PTPN2 in T cells accelerated type 1 diabetes onset, colitis, and Sjögren syndrome — illustrating the consequences of unchecked JAK-STAT activity in immune cells. At the clinical level, this genotype's most direct evidence is for psoriasis, where GWAS established genome-wide significant association (p ≈10⁻¹¹). The shared mechanistic pathway means inflammatory conditions driven by excess JAK-STAT signaling — psoriatic arthritis, Crohn's disease, ulcerative colitis, type 1 diabetes, rheumatoid arthritis — are all potentially relevant.

For existing inflammatory disease, PTPN2 GG genotype may be particularly informative for biologic selection: studies of PTPN2 risk variants show improved anti-TNF response and reduced anti-IL-12/23 response in inflammatory bowel disease patients. JAK inhibitors, which target the exact pathway PTPN2 normally dampens, represent a mechanistically aligned treatment option for this genotype when clinically indicated.